Criminal or bystander: Imatinib and second primary malignancy in GIST patients

Chinese Journal of Cancer Research

Volumn 25, Issue 5, 2013, Pages 490-492

  Kanda, Tatsuo ^a  

^a Department of Surgery Sanjo General Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

ADVANCED CANCER; AUTOPSY; CANCER INCIDENCE; CANCER RISK; CARCINOGENESIS; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; EDITORIAL; ESOPHAGUS CANCER; GASTRECTOMY; GASTROINTESTINAL STROMAL TUMOR; HUMAN; KIDNEY CANCER; LEIOMYOSARCOMA; NEURILEMOMA; SECOND CANCER; STOMACH CANCER;

EID: 84901642655     PISSN: 10009604     EISSN: 19930631     Source Type: Journal    
DOI: 10.3978/j.issn.1000-9604.2013.10.15     Document Type: Editorial

References (17)

1. Kanda T, Ishikawa T, Hirota S, et al. Prospective observational study of imatinib therapy in Japanese patients with advanced gastrointestinal stromal tumors: long-term follow-up and second malignancy. Jpn J Clin Oncol 2012;42:578-85.
2. Phan K, Martires K, Kurlander DE, et al. The incidence of second primary malignancies after gastrointestinal stromal tumor before and after the introduction of imatinib mesylate. Transl Cancer Res 2013. [Epub ahead of print].
3. Ruka W, Rutkowski P, Nowecki Z, et al. Other malignant neoplasms in patients with gastrointestinal stromal tumors (GIST). Med Sci Monit 2004;10:LE13-4. (Pubitemid 39166446)
4. Agaimy A, Wünsch PH, Sobin LH, et al. Occurrence of other malignancies in patients with gastrointestinal stromal tumors. Semin Diagn Pathol 2006;23:120-9. (Pubitemid 44692421)
5. Wronski M, Ziarkiewicz-Wroblewska B, Gornicka B, et al. Synchronous occurrence of gastrointestinal stromal tumors and other primary gastrointestinal neoplasms. World J Gastroenterol 2006;12:5360-2.
6. Liszka Ł, Zielińska-Pajak E, Pajak J, et al. Coexistence of gastrointestinal stromal tumors with other neoplasms. J Gastroenterol 2007;42:641-9. (Pubitemid 47278689)
7. Pandurengan RK, Dumont AG, Araujo DM, et al. Survival of patients with multiple primary malignancies: a study of 783 patients with gastrointestinal stromal tumor. Ann Oncol 2010;21:2107-11.
8. Gonçalves R, Linhares E, Albagli R, et al. Occurrence of other tumors in patients with GIST. Surg Oncol 2010;19:e140-3.
9. Sevinc A, Seker M, Bilici A, et al. Co-existence of gastrointestinal stromal tumors with other primary neoplasms. Hepatogastroenterology 2011;58:824-30.
10. Agaimy A, Wünsch PH, Hofstaedter F, et al. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol 2007;31:113-20. (Pubitemid 46036910)
11. Kawanowa K, Sakuma Y, Sakurai S, et al. High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum Pathol 2006;37:1527-35. (Pubitemid 44792229)
12. Joensuu H, Vehtari A, Riihimäki J, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol 2012;13:265-74.
13. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008;26:620-5. (Pubitemid 351264357)
14. National Cancer Institute. Cancer statics review 1975-2010; Surveillance Epidemiology and End Results (online). Available online: http://seer.cancer.gov/ csr/1975-2010/15.
15. Novartis. Glivec (imatinib esylate tablets): JPN prescribing information (online). Available online: http://product.novartis.co.jp/gli/pi/pi-glitab.pdf
16. Au WY, Ho KH, Shek TW. Papillary renal cell carcinoma and gastrointestinal stromal tumor: a unique association. Ann Oncol 2004;15:843-4. (Pubitemid 38714751)
17. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol 2010;28:1247-53.